Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Stoke Therapeutics, Inc. - Common Stock
(NQ:
STOK
)
26.42
+0.35 (+1.34%)
Delayed Quote
Updated: 11:53 AM EST, Nov 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Stoke Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Stoke (STOK) Q3 2026 Earnings Call Transcript
↗
October 30, 2026
Dravet syndrome trial enrollment exceeded targets with zero discontinuations.
Via
The Motley Fool
Topics
Earnings
Stoke Therapeutics Q3 Earnings Call Highlights
↗
October 29, 2026
Stoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR trial of zorevunersen in Dravet syndrome is advancing toward a planned third-quarter 2027 data readout, while the company prepares for a...
Via
MarketBeat
Topics
Earnings
Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts
↗
August 17, 2026
Stoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR study of zorevunersen for Dravet syndrome has enrolled 162 patients, exceeding its target enrollment of 150, with no patient discontinuations...
Via
MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Beats Q1 2026 Estimates as Phase 3 Trial Nears Completion
↗
May 07, 2026
Via
Chartmill
Earnings Scheduled For November 4, 2025
↗
November 04, 2025
Via
Benzinga
Where Stoke Therapeutics Stands With Analysts
↗
August 13, 2025
Via
Benzinga
A Look Ahead: Stoke Therapeutics's Earnings Forecast
↗
August 11, 2025
Via
Benzinga
Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript
↗
August 10, 2026
Phase III enrollment complete for zorevunersen with zero discontinuation rates.
Via
The Motley Fool
Topics
Earnings
Stoke Therapeutics Q2 Earnings Call Highlights
↗
August 03, 2026
Stoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR study of zorevunersen in patients with Dravet syndrome remains on track for a data readout in the third quarter of 2027, following completion...
Via
MarketBeat
Topics
Earnings
Stoke Therapeutics Q1 Earnings Call Highlights
↗
May 09, 2026
Stoke Therapeutics (NASDAQ:STOK) said its lead investigational therapy zorevunersen continued to show durable seizure reductions and improvements in measures of cognition and behavior in four-year...
Via
MarketBeat
Topics
Earnings
Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares
↗
March 27, 2026
This biotech innovator in genetic disease therapies reported a notable insider sale amid a year of dramatic share price gains.
Via
The Motley Fool
Topics
Regulatory Compliance
Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss
March 26, 2026
The biotechnology landscape witnessed a defining moment on March 26, 2026, as Wave Life Sciences (Nasdaq: WVE) released highly anticipated interim Phase 1 data from its INLIGHT trial. The study, which...
Via
MarketMinute
Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally
↗
March 24, 2026
This RNA therapeutics innovator for rare diseases reported a notable insider sale amid a year of dramatic share price gains.
Via
The Motley Fool
Topics
Regulatory Compliance
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million
↗
February 22, 2026
Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.
Via
The Motley Fool
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%
↗
February 22, 2026
This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.
Via
The Motley Fool
Topics
Regulatory Compliance
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year
↗
February 22, 2026
This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025
↗
February 22, 2026
Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26%
↗
February 22, 2026
Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.
Via
The Motley Fool
Topics
Regulatory Compliance
Top movers in Monday's pre-market session
↗
January 12, 2026
Via
Chartmill
Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell?
↗
December 10, 2025
This biotech targeting rare genetic diseases reported a notable insider sale following a year of rapid share price gains.
Via
The Motley Fool
Topics
Regulatory Compliance
Curious about the stocks that are showing activity after the closing bell on Tuesday?
↗
December 09, 2025
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via
Chartmill
6 Analysts Have This To Say About Stoke Therapeutics
↗
November 05, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
November 04, 2025
Via
Benzinga
Examining the Future: Stoke Therapeutics's Earnings Outlook
↗
November 03, 2025
Via
Benzinga
What 4 Analyst Ratings Have To Say About Stoke Therapeutics
↗
October 10, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
July 22, 2025
Via
Benzinga
D.R. Horton, IQVIA Holdings, Northrop Grumman And Other Big Stocks Moving Higher On Tuesday
↗
July 22, 2025
Via
Benzinga
Earnings Scheduled For August 12, 2025
↗
August 12, 2025
Via
Benzinga
This Verint Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
↗
July 18, 2025
Via
Benzinga
STOKE THERAPEUTICS INC (NASDAQ:STOK) – A Biotech Stock with Strong Growth Signals
↗
May 29, 2025
STOKE THERAPEUTICS (NASDAQ:STOK) shows strong growth metrics, high profitability improvements, and attractive valuation, making it a candidate for growth investors following Louis Navellier's...
Via
Chartmill
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
